Thursday, 7 June 2012

Linagliptin-Tradjenta-Eli Lilly

Tradjenta drug shows efficacy against type 2 diabetes

Boehringer Ingelheim and Eli Lilly have announced the data from the Phase 3 study of once-daily Tradjenta (linagliptin) 5mg tablets, used as an adjunct to diet and exercise to improve glycemic control in black or African American adults with type 2 d… (Source: Drug Development Technology)MedWorm Sponsor Message: Please have a look at this new site driven by MedWorm: The Breast Cancer Daily read more..

No comments:

Post a Comment